期刊
JOURNAL OF CYSTIC FIBROSIS
卷 19, 期 1, 页码 108-113出版社
ELSEVIER
DOI: 10.1016/j.jcf.2019.06.016
关键词
Lung function; Respiratory symptom score; Sputum microbial density; Exacerbations; Quality of life
资金
- NIH [U01 HL102288]
- Cystic Fibrosis Foundation RDP [R458]
- Institute for Clinical and Translational Science grant (NIH)
- Institute for Clinical and Translational Science grant (CTSA grant) [UL1TR002537]
Background: Cystic fibrosis (CF) lung disease is characterized by chronic bacterial infection and recurrent pulmonary exacerbations. Xylitol is a 5-carbon sugar that can lower the airway surface salt concentration and augment innate immunity. We examined the safety and efficacy of aerosolized xylitol use for 2 weeks in subjects hospitalized with a pulmonary exacerbation of CF. Methods: In a 2-week study, 60 subjects with cystic fibrosis and FEV1 > 30% predicted were enrolled to receive aerosolized 7% hypertonic saline (4 ml) or 15% xylitol (5 ml) twice a day for 14days. Outcomes assessed included change from baseline in FEV1% predicted, change in sputum microbial density, revised CF quality of life questionnaire including the respiratory symptom score, time to next hospitalization for a pulmonary exacerbation, and frequency of adverse events. Results: 59 subjects completed the study (one subject in the saline group withdrew before any study product administration). No significant differences were noted between the 2 arms in mean changes in lung function, sputum microbial density for Pseudomonas aeruginosa and Staphylococcus aureus, body weight, quality of life, and frequency of adverse events. Conclusions: Aerosolized hypertonic xylitol was well-tolerated among subjects hospitalized for CF pulmonary exacerbation. Future studies examining efficacy for long term use in patients with CF lung disease would be worthwhile. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据